The Argentine Supreme Court has recently issued a significant decision that may shape future healthcare litigation involving high-cost pharmaceuticals and the obligations of health insurers.
In “G. B., R. v. OSDE s/ Health Protection Action” (Recurso de Queja No. 1), the Court set aside a lower appellate judgment that had ordered a private health insurer to continue providing the imported drug Trikafta to a patient suffering from cystic fibrosis.
Importantly, the Supreme Court did not question the patient’s right to comprehensive medical coverage. Rather, the dispute focused on whether a healthcare provider can be compelled to finance an imported medicine when an equivalent domestic alternative has been approved by Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT).
The Court found that the appellate decision was arbitrary because it selectively assessed the evidence. In particular, it overlooked the findings of the Court’s Medical Board, which concluded that there was no medical contraindication to replacing the imported drug with Trixacar, an ANMAT-approved domestic alternative. The Court further observed that the lower court’s requirement for additional bioequivalence studies lacked support under the applicable regulatory framework.
Why the Decision Matters
Beyond the facts of the individual case, the ruling is noteworthy for several reasons.
First, it reinforces the principle that judicial decisions in healthcare disputes must be grounded on a comprehensive assessment of scientific and expert evidence.
Second, it recognises the importance of the national regulatory approval process and the technical authority of ANMAT in determining the safety and efficacy of pharmaceutical products.
Finally, the judgment may have broader implications for future disputes involving high-cost therapies, innovative medicines, reimbursement obligations and the balance between patients’ rights and the sustainability of healthcare systems.
As healthcare litigation continues to expand in Argentina, this decision provides valuable guidance on the interaction between judicial review, medical evidence and pharmaceutical regulation.
For companies operating in the life sciences, healthcare and insurance sectors, the case is another reminder that regulatory compliance and scientific evidence remain central to the resolution of complex healthcare disputes.